Format

Send to

Choose Destination
Genome Med. 2017 Jan 12;9(1):2. doi: 10.1186/s13073-016-0395-8.

Emerging links between m6A and misregulated mRNA methylation in cancer.

Author information

1
Department of Pharmacology, Weill Cornell Medical College, Cornell University, New York, NY, 10065, USA. srj2003@med.cornell.edu.
2
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kharasm@mskcc.org.

Abstract

N 6-methyladenosine (m6A) in mRNA has emerged as a crucial epitranscriptomic modification that controls cellular differentiation and pluripotency. Recent studies are pointing to a role for the RNA methylation program in cancer self-renewal and cell fate, making this a new and promising therapeutic avenue for investigation.

PMID:
28081722
PMCID:
PMC5228104
DOI:
10.1186/s13073-016-0395-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center